FDA Halts Rocket Pharma’s Gene Therapy Trial After Patient Death and 63% Stock Plunge
In a significant development, the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Rocket Pharmaceuticals’ mid-stage gene therapy trial following the death of a patient. The trial was evaluating RP-A501, an experimental treatment for Danon disease—a rare genetic disorder affecting heart and muscle function. The patient developed capillary leak syndrome, leading to severe complications and subsequent death.
Rocket Pharmaceuticals has voluntarily paused further dosing and is collaborating with the FDA and medical experts to investigate the incident. The company has not provided a timeline for resuming the trial.
The news had an immediate impact on Rocket Pharma’s stock, which plummeted by 63% in premarket trading, falling from $6.27 to $2.30.
You May Interested In
2026-07-25
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Slams Door on Chinese Food Exports: Inspection Refusals Trigger Automatic Detentions
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
EU Biocidal Data Protection Extension Raises the Stakes for Chemical Market Entry
-
Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies
-
Your Plant Has the Data. Your AI Cannot Reach It. Here Is Why That Is the Core Problem in Chemical Manufacturing.
-
FDA Dye Pledges Push Natural Colors Into the Mainstream
Recommend Reading
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
GM Crop Area Reaches 216 Million Hectares
-
GM Crop Area Reaches 216 Million Hectares
-
FDA Delays Beetroot Red and Spirulina Color Orders
-
This Week's TDI Market Rises to a High Level (3.23-3.27) in China
-
The market price of propylene oxide shows a differentiated pattern of short-term low and medium-to-long-term medium-high positions in China
-
China's Natural Rubber Market Weakly Consolidates
-
Upward Momentum Fades, Formic Acid Prices Return to Stable Operation
-
Ethylene Glycol Prices Recently Stop Declining—Beware of a Downward Spiral Triggered by a Sharp Drop in Crude Oil Prices